Tags

Type your tag names separated by a space and hit enter

Anandamide dysfunction in prodromal and established psychosis.
Curr Pharm Des 2012; 18(32):5188-93CP

Abstract

There is epidemiological evidence that frequent cannabis use in general and during puberty in particular increases the risk to suffer psychosis and psychotic symptoms. Based on these observations, there is growing interest in the role of the endogenous cannabinoid system (eCB system) - the point of action for psychoactive cannabinoids - in psychiatric disorders and schizophrenia in particular. It has been hypothesized nearly two decades ago that the eCB system may play a pathophysiological role in schizophrenia either in terms of an endogenous malfunction of the system itself and/or of a secondary malfunction as a result of the use of exogenous cannabinoids like Δ(9)-tetrahydrocannabinol, the major psychoactive phytocannabinoid in Cannabis sativa. To test this hypothesis, several studies have been performed investigating endogenous ligands to cannabinoid CB1-receptors such as anandamide both in cerebrospinal fluid and plasma of patients and controls. Here a mini-review of the role of anandamide in schizophrenia is provided.

Authors+Show Affiliations

Dept. of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, J5,68159 Mannheim, Germany. leweke@cimh.de

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

22716147

Citation

Leweke, F Markus. "Anandamide Dysfunction in Prodromal and Established Psychosis." Current Pharmaceutical Design, vol. 18, no. 32, 2012, pp. 5188-93.
Leweke FM. Anandamide dysfunction in prodromal and established psychosis. Curr Pharm Des. 2012;18(32):5188-93.
Leweke, F. M. (2012). Anandamide dysfunction in prodromal and established psychosis. Current Pharmaceutical Design, 18(32), pp. 5188-93.
Leweke FM. Anandamide Dysfunction in Prodromal and Established Psychosis. Curr Pharm Des. 2012;18(32):5188-93. PubMed PMID: 22716147.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Anandamide dysfunction in prodromal and established psychosis. A1 - Leweke,F Markus, PY - 2012/03/30/received PY - 2012/05/04/accepted PY - 2012/6/22/entrez PY - 2012/6/22/pubmed PY - 2013/3/26/medline SP - 5188 EP - 93 JF - Current pharmaceutical design JO - Curr. Pharm. Des. VL - 18 IS - 32 N2 - There is epidemiological evidence that frequent cannabis use in general and during puberty in particular increases the risk to suffer psychosis and psychotic symptoms. Based on these observations, there is growing interest in the role of the endogenous cannabinoid system (eCB system) - the point of action for psychoactive cannabinoids - in psychiatric disorders and schizophrenia in particular. It has been hypothesized nearly two decades ago that the eCB system may play a pathophysiological role in schizophrenia either in terms of an endogenous malfunction of the system itself and/or of a secondary malfunction as a result of the use of exogenous cannabinoids like Δ(9)-tetrahydrocannabinol, the major psychoactive phytocannabinoid in Cannabis sativa. To test this hypothesis, several studies have been performed investigating endogenous ligands to cannabinoid CB1-receptors such as anandamide both in cerebrospinal fluid and plasma of patients and controls. Here a mini-review of the role of anandamide in schizophrenia is provided. SN - 1873-4286 UR - https://www.unboundmedicine.com/medline/citation/22716147/Anandamide_dysfunction_in_prodromal_and_established_psychosis_ L2 - http://www.eurekaselect.com/102853/article DB - PRIME DP - Unbound Medicine ER -